Joshua H. Bilenker, President & CEO at Loxo Oncology, Inc. (LOXO), sold 28,397 shares at $177.44 ($5.1M) on 2018-06-19, disclosed to the SEC on 2018-06-21.
Open-market sale of $5.1M LOXO by President & CEO. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $176.20 | 2,336 | $412K | 8.1% |
| 2 | $177.06 | 3,427 | $607K | 12.0% |
| 3 | $177.44 | 8,232 | $1.5M | 28.9% |
| 4 | $178.12 | 1,737 | $309K | 6.1% |
| 5 | $178.30 | 8,763 | $1.6M | 30.9% |
| 6 | $179.83 | 3,902 |
| $702K |
| 13.9% |
| Total | $177.93 avg | 28,397 | $5.1M | 100% |
| Filing → |
| LOXO | SELL | 2018-12-12 | $2.7M | — | Filing → |
| LOXO | SELL | 2018-12-12 | $1.0M | — | Filing → |
| LOXO | SELL | 2018-11-28 | $1.2M | — | Filing → |